These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15288481)

  • 1. Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation.
    Toniutto P; Fabris C; Bortolotti N; Minisini R; Avellini C; Fumo E; Pirisi M
    J Hepatol; 2004 Aug; 41(2):307-11. PubMed ID: 15288481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.
    Machicao VI; Bonatti H; Krishna M; Aqel BA; Lukens FJ; Nguyen JH; Rosser BG; Satyanarayana R; Grewal HP; Hewitt WR; Harnois DM; Crook JE; Steers JL; Dickson RC
    Transplantation; 2004 Jan; 77(1):84-92. PubMed ID: 14724440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
    Neumann UP; Berg T; Bahra M; Seehofer D; Langrehr JM; Neuhaus R; Radke C; Neuhaus P
    J Hepatol; 2004 Nov; 41(5):830-6. PubMed ID: 15519657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C.
    D'Souza RF; Feakins R; Mears L; Sabin CA; Foster GR
    Aliment Pharmacol Ther; 2005 Mar; 21(5):519-24. PubMed ID: 15740534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients.
    Takada Y; Haga H; Ito T; Nabeshima M; Ogawa K; Kasahara M; Oike F; Ueda M; Egawa H; Tanaka K
    Transplantation; 2006 Feb; 81(3):350-4. PubMed ID: 16477219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C.
    Toniutto P; Fabris C; Falleti E; Cussigh A; Fontanini E; Bitetto D; Fornasiere E; Minisini R; De Feo T; Marangoni F; Pirisi M
    Liver Int; 2008 Feb; 28(2):257-63. PubMed ID: 17900242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation.
    Rigamonti C; Donato MF; Fraquelli M; Agnelli F; Ronchi G; Casazza G; Rossi G; Colombo M
    Gut; 2008 Jun; 57(6):821-7. PubMed ID: 18218676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.
    Shiffman ML; Stravitz RT; Contos MJ; Mills AS; Sterling RK; Luketic VA; Sanyal AJ; Cotterell A; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Oct; 10(10):1248-55. PubMed ID: 15376308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
    Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
    Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Cabrera R; Shuster JJ; Theriaque D; Reed AI; Hemming AW; Liu C; Crawford JM; Nelson DR
    Liver Transpl; 2004 Oct; 10(10):1240-7. PubMed ID: 15376304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
    Belli LS; Burroughs AK; Burra P; Alberti AB; Samonakis D; Cammà C; De Carlis L; Minola E; Quaglia A; Zavaglia C; Vangeli M; Patch D; Dhillon A; Cillo U; Guido M; Fagiuoli S; Giacomoni A; Slim OA; Airoldi A; Boninsegna S; Davidson BR; Rolles K; Pinzello G
    Liver Transpl; 2007 May; 13(5):733-40. PubMed ID: 17370330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
    Carpino G; Morini S; Ginanni Corradini S; Franchitto A; Merli M; Siciliano M; Gentili F; Onetti Muda A; Berloco P; Rossi M; Attili AF; Gaudio E
    Dig Liver Dis; 2005 May; 37(5):349-56. PubMed ID: 15843085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.
    Toniutto P; Fabris C; Bitetto D; Falleti E; Avellini C; Rossi E; Smirne C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1904-8. PubMed ID: 17914968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
    Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
    Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression.
    Alkhouri N; Hanouneh IA; Lopez R; Zein NN
    Liver Transpl; 2010 Feb; 16(2):155-62. PubMed ID: 20104483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C.
    Russo MW; Firpi RJ; Nelson DR; Schoonhoven R; Shrestha R; Fried MW
    Liver Transpl; 2005 Oct; 11(10):1235-41. PubMed ID: 16184580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection.
    Rifai K; Sebagh M; Karam V; Saliba F; Azoulay D; Adam R; Castaing D; Bismuth H; Reynès M; Samuel D; Féray C
    J Hepatol; 2004 Sep; 41(3):446-53. PubMed ID: 15336448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.
    Burra P; Loreno M; Russo FP; Germani G; Galligioni A; Senzolo M; Cillo U; Zanus G; Fagiuoli S; Rugge M
    Liver Transpl; 2009 Jun; 15(6):619-28. PubMed ID: 19479805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.